Pozanicline (ABT-089) 是一种新型的胆碱能药物，是 α4β2* nAChRs 部分激动剂，显示对 α6β2* 和 α4α5β2 nAChR 亚型的高选择性。Pozanicline 与 [3H] cytisine位点的结合亲和力 (Ki; rat) 为 16.7 nM。Pozanicline 逆转尼古丁戒断诱导的认知缺陷，可能是尼古丁成瘾的新治疗策略的有效组成部分。
Pozanicline (ABT-089) selectively activate neuronal nicotinic acetylcholine receptor (nAChR) subtypes, is a novel cholinergic agent that is a partial agonist at α4β2* nAChRs (Ki=16 nM) and shows high selectivity for α6β2* and α4α5β2 nAChR subtypes, the binding affinity (Ki, rat) for Pozanicline to [3H] cytisine sites is 16.7 nM.Pozanicline reverses nicotine withdrawal-induced cognitive deficits, may be an effective component of novel therapeutic strategies for nicotine addiction[1]. Ki: 16 nM (α4β2* nAChR)[1]
[1]. Sullivan JP, et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther. 1997 Oct;283(1):235-46. [2]. Yildirim E, et al. ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice. Behav Pharmacol. 2015 Apr;26(3):241-8.
动态评分
0.0